Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Core Insights - Disc Medicine, Inc. is set to present clinical data on its drug DISC-0974 at the 2025 American Society of Nephrology Kidney Week, focusing on patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia [1][2] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious hematologic diseases, with a focus on innovative therapeutic candidates targeting red blood cell biology, heme biosynthesis, and iron homeostasis [5] Clinical Study Details - The upcoming presentation will include data from a Phase 1b, randomized, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of DISC-0974, along with pharmacodynamic activity measures such as hepcidin and iron levels [2][4] - The presentation is scheduled for November 8, 2025, at 10:00 am CST, with the abstract available on the ASN Kidney Week conference website [3][4]